

**F. No. 6/32/2025-DGTR**  
**Government of India**  
**Department of Commerce**  
**Ministry of Commerce & Industry**  
**(Directorate General of Trade Remedies)**  
**4<sup>th</sup> Floor, Jeevan Tara Building 5,**  
**Parliament Street, New Delhi – 110001**

**Date:** 30<sup>th</sup> October 2025

**Case No. AD (OI)-29/2025**

**To,**

**All interested parties**

**Subject: PUC/PCN methodology in the anti-dumping investigation concerning imports of Bis (2,2,6,6-Tetramethyl-4-Peridyl) Sebacate (UV 770) originating in or exported from the European Union and China PR.**

1. Attention of all interested parties is invited to the above-mentioned investigation initiated vide Notification No. 6/32/2025-DGTR dated 27<sup>th</sup> September 2025. The non-confidential version of the application filed by the domestic industry was intimated to all interested parties vide Letter/Email dated 7<sup>th</sup> October 2025.
2. Whereby, the interested parties were granted an opportunity to present their comments on the scope of the product under consideration (PUC), and product control number (PCN) methodology, within a period of 15 days from the date of intimation, which ended on **22<sup>nd</sup> October 2025**.
3. The product under consideration (hereinafter referred to as “PUC”) was defined as under:

*“3. The product under consideration is Bis (2,2,6,6-Tetramethyl-4-piperidyl) Sebacate, also known as UV 770 or Hindered Amines Light Stabilizer 770 (HALS 770). The product under consideration is a low molecular weight organic compound with chemical formula C<sub>28</sub>H<sub>52</sub>N<sub>2</sub>O<sub>4</sub>, having CAS number 52829-07-9. It is colourless to pale yellow in colour*

*4. The product under consideration is a UV light stabiliser, used to prevent degradation of polymers from exposure to ultraviolet radiation or sunlight, which result in increased life of products. The product under consideration is also referred to as UV Stabilizer 770 or Light Stabilizer 770, and is available under multiple brand names, including but not limited to Tinuvin 770, Sabostab 77, Riasorb 770 and Sunovin 770.”*

4. No PCN methodology was proposed in the initiation notification.
5. No comments have been received from any interested party on the scope of the product

or PCN.

6. The Authority adopts the same scope of product under consideration as notified in the initiation Notification No. 6/32/2025-DGTR dated 27<sup>th</sup> September 2025 without any changes. No PCNs are adopted in this case.
7. Accordingly, all interested parties are directed to file their questionnaire response based on the above product under consideration within 37 days from the date of intimation of Letter/E-mail dated 7<sup>th</sup> October 2025 i.e., by 13<sup>th</sup> November, 2025.
8. This communication is limited to clarifying the scope of the product under consideration for which the present investigation is being conducted. This does not preclude interested parties from providing relevant information and evidence to substantiate their requests for exclusion for any particular product. The Authority shall decide the scope of the product under consideration for any measures recommended, after considering relevant information and evidence furnished by all interested parties during the course of investigation.
9. This issues with the approval of the Designated Authority.

Sd/-  
C.K. Mishra  
Director (FT)  
Email - [jd11-dgtr@gov.in](mailto:jd11-dgtr@gov.in)